medigraphic.com

2019, Number 4

<< Back Next >>

Rev Hematol Mex 2019; 20 (4)

Acute lymphoblastic leukemia. Genetic mechanisms

López-Hernández G

Language: Spanish
References: 13
Page: 273-277
PDF size: 276.02 Kb.


ABSTRACT

Acute lymphoblastic leukemia is the most common malignancy of childhood. It’s a genetically complex entity that persists as an important cause of mortality related to childhood cancer. Its current therapeutic success is product of advances in the understanding of its genomic profile, resulting in the precise allocation of risk based on the biological and clinical characteristics of patients at diagnosis, as well as the response to treatment with appropriate modulation of chemotherapy intensity. This review describes the current genetic picture of pediatric acute lymphoblastic leukemia.


REFERENCES

  1. Rivera-Luna R, Leal-Leal C, Cárdenas-Cardós R y col. A survey of 4,076 children with cancer. Certain epidemiological aspects from a single Institution. Bol Med Hosp Infant Mex 1996;53:598-605.

  2. Brisson GD, Alves LR, Pombo-de-Oliveira MS. Genetic susceptibility in childhood acute leukaemias: a systematic review. Ecancermedicalscience 2015;14 (9):539. doi: 10.3332/ecancer.2015.539.

  3. Tasian SK, Loh ML, Hunger SP. Childhood acute lymphoblastic leukemia: Integrating genomics into therapy. Cancer 2015;121(20):3577-90. doi: 10.1002/cncr.29573.

  4. Pieters R, Carroll W. Biology and treatment of acute lymphoblastic leukemia. Pediatr Clin North Am 2008;55:1-20. doi: 10.1016/j.pcl.2007.11.002.

  5. Tasian SK, Hunger SP. Genomic characterization of paediatric acute lymphoblastic leukaemia: an opportunity for precision medicine therapeutics. Br J Haematol 2017;176(6):867-882. doi: 10.1111/bjh.14474.

  6. Safavi S, Paulsson K. Near-haploid and low-hypodiploid acute lymphoblastic leukemia: two distinct subtypes with consistently poor prognosis. Blood 2017;129(4):420-423. doi: 10.1182/blood-2016-10-743765.

  7. Roberts KG. Genetics and prognosis of ALL in children vs adults. Hematology Am Soc Hematol Educ Program 2018;1:137-145. doi: 10.1182/asheducation-2018.1.137.

  8. Jeha S, Pei D, Raimondi SC, et al. Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3- PBX1. Leukemia 2009;23:1406-1409. doi: 10.1038/ leu.2009.42.

  9. Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome– positive acute lymphoblastic leukemia: A children’s oncology group study. J Clin Oncol 2009;27(31):5175-5181. doi: 10.1200/JCO.2008.21.2514.

  10. Schultz KR, Carroll A, Heerema NA, et al. Long-term followup of imatinib in pediatric Philadelphia chromosomepositive acute lymphoblastic leukemia: Children’s Oncology Group Study AALL0031. Leukemia 2014;28(7):1467-1471. doi: 10.1038/leu.2014.30.

  11. Pui CH, Roberts KG, Yang JJ, Mullighan CG. Philadelphia chromosome-like acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk 2017;17(8):464-470. doi: 10.1016/j. clml.2017.03.299

  12. Roberts KG. The biology of Philadelphia chromosome-like ALL. Best Pract Res Clin Haematol 2017;30(3):212-221. doi: 10.1016/j.beha.2017.07.003.

  13. Khan M, Siddiqi R, Tran TH. Philadelphia chromosome-like acute lymphoblastic leukemia: A review of the genetic basis, clinical features, and therapeutic options. Semin Hematol 2018;55(4):235-241. doi: 10.1053/j.seminhematol. 2018.05.001.




2020     |     www.medigraphic.com